Unilever’s Food Division Insider Sells as Smart Money Bets on McCormick’s Takeover Play

Unilever has signed a definitive deal to sell its Lawry's and Adolph's seasoning brands to McCormick for $605 million in cash. On the surface, this is a clean exit from a niche, low-growth segment. The brands generated just $150 million in sales last year. But this divestment is just the opening move in a much larger strategic pivot. The company is now exploring a potential complete or partial sale of its entire food division, a move that could be worth several tens of billions of dollars.

The setup is clear. Unilever is accelerating its refocus away from food and toward its higher-growth beauty, personal care, and wellbeing sectors. It has already shed other food assets like its margarine and meat substitute businesses, and even took its ice cream division public. The Lawry's/Adolph's sale fits this pattern of streamlining. Yet, here's where the smart money's signal gets interesting. Despite this announced strategic shift, a key insider just took money off the table.

On March 6, Heiko Schipper, Business Group President, Foods, sold 2,600 Unilever shares at €58.03 each. The total value of that transaction was €150,872.37. This is not a trivial sale by a junior executive. Schipper is a member of the company's leadership executive, directly responsible for the very division now being dissected. His sale, reported just days after the McCormick deal was announced, creates a critical disconnect.

The thesis here is straightforward. The company is signaling a strategic pivot to investors. But the insider selling suggests the smart money is hedging its bets. When the person running the division you're planning to sell off is quietly cashing out, it raises a question about the timing and the true confidence behind the plan. It's a classic sign of skin in the game being reduced, even as the corporate narrative pushes forward.

The Financial Reality: Growth Stalls, Guidance is Cautious

The numbers tell a story of a company hitting a wall. Unilever's full-year 2025 results showed underlying sales growth of just 3.5%. That's a solid figure, but it's also the kind of mid-single-digit pace that struggles to excite investors in a market demanding higher returns. More telling is the forward guidance. Management has set its sights for 2026 organic sales growth at the lower end of its medium-term range of 4% to 6%. This cautious positioning, described by analysts as "spicy" given the ambitious targets, signals a business that expects a slower start.

Analysts have already reacted with skepticism. Following the results, they downgraded the stock, citing valuation concerns and the difficulty of hitting the company's own 2026 growth and margin targets. The market's verdict has been a cool one. Despite a €1.5 billion share buyback announced alongside the results, shares have declined, reflecting a wait-and-see attitude. The setup is clear: the strategic pivot is underway, but the core business is not accelerating.

This creates a tension between the company's narrative and the smart money's patience. Institutional investors are clearly divided. While some are accumulating, the net flow shows a significant number of funds reducing their positions. In the most recent quarter, 1,121 institutions decreased their holdings, including major players like Morgan Stanley and GQG Partners, which exited entirely. This institutional accumulation is real, but it's being offset by a wave of selling. The bottom line is that the market is not betting heavily on a near-term turnaround, waiting instead for clearer proof that the beauty and personal care pivot can lift the entire company.

The Smart Money Moves: Insiders and Institutions

The real story isn't in the headlines about Unilever's divestment. It's in the filings that show who is putting skin in the game at the other end of the deal. The key institutional move here is a clear, long-term accumulation signal from the buyer's side.

McCormick's CEO, Brendan Foley, filed a Schedule 13D in late 2025, a legal disclosure that signals a significant, non-trivial stake. As of February 6, 2026, he beneficially owns 790,496 shares, representing 5.1% of the company's outstanding shares. This is not a casual holding. It's the CEO of the acquiring company staking a major claim in the business he's now leading. This kind of filing, coupled with his role as a reporting person, shows a deep alignment of interest and a bet on the long-term value of the combined entity.

The institutional picture is more mixed but reveals a core of stability. The Vanguard Group remains McCormick's largest shareholder, owning 12.73% of the company. This massive, long-term holder provides a floor of support. Other major funds like State Street and BlackRock have been adding shares recently, indicating institutional accumulation. Yet, there are also signs of selective trimming, like a Vanguard cut of 66,000 shares. The bottom line is that the smart money is not all-in, but the largest players are either holding firm or buying in, which is a stronger signal than a wave of selling.

Then there are the congressional signals, which are a classic case of noise. Recent trading shows a split: members like Ro Khanna have been buying, while others like Julia Letlow have been selling. These trades are often small and can be driven by personal financial planning, not a macro view of the company's strategy. They don't move the needle like a CEO's 13D filing or a major fund's sustained accumulation.

The setup is clear. The smart money at McCormick is betting on the deal's success, with the CEO himself taking a major position. Meanwhile, at Unilever, the insider selling from the division head creates a stark contrast. When the buyer's leadership is buying, and the seller's leadership is selling, the real signal is in the direction of the capital.

Catalysts and Risks: What to Watch Next

The next major catalyst is not a quarterly report, but a timeline. Any formal announcement on the potential sale of Unilever's entire food division is not expected before 2027. The company has begun preliminary discussions with advisors, but no decision has been made. For now, the setup is a long wait. The market's patience is being tested, and the smart money is watching for the first concrete signal that this strategic pivot is moving from talk to transaction.

The immediate watchlist is simple: follow the insider moves. At Unilever, further selling from executives like Heiko Schipper would reinforce the skepticism signal. At McCormick, any continued buying from CEO Brendan Foley or other insiders would confirm their skin in the game. These filings are the real-time pulse of alignment.

The biggest risk is that the plan stalls. If the food business sale is delayed or abandoned, Unilever is left with a portfolio that continues to underperform. The core food brands face headwinds from budget-conscious consumers, while the ambitious 2026 growth and margin targets are already seen as difficult to achieve. The analyst concern is clear: the operational transformation is ongoing, but the stock has rallied above valuation support, leaving little room for error. If the strategic exit doesn't materialize, the company could be stuck with a growth-challenged legacy business while its beauty pivot takes time to lift the overall results.